Key Takeaways
- India business powers 15% Q4 growth: One India delivered robust double-digit expansion across branded Rx, trade generics and consumer health, with chronic therapies now at 60% of the mix.
- U.S. respiratory pipeline unlocks: First AB-rated generic Ventolin approved with 6-month CGT exclusivity, launch in Q1; three more respiratory assets expected in FY27, supporting a $1 billion run-rate target by year-end.
- Margin recovery is back-half loaded: FY27 EBITDA guided to 18.5%–20%, with sequential improvement quarter-on-quarter and the key step-up concentrated in H2 as new launches scale and facility costs get absorbed.
- Biosimilars bet gets explicit: Management called it a $200 billion opportunity over the next decade, with a JV in place, two in-house assets under development, and a plan to add 1–2 assets each year toward a 6–8 asset pipeline.
- What to watch next quarter: Ventolin launch execution and initial offtake, Advair approval timing, Lanreotide remediation visibility, and whether the India growth momentum sustains past a seasonally weak Q1.
India Business: The Growth Engine
- Broad-based strength: All three segments (branded prescription, trade generics, consumer health) delivered strong double-digit growth in Q4, lifting full-year growth to 9% YoY. Chronic therapies including respiratory, anti-diabetes, cardiac and urology all grew at strong double-digit rates.
- Foracort crosses a milestone: The flagship inhalation brand surpassed ₹1,000 crores in revenue, reinforcing Cipla's respiratory market leadership. Cardiac brand Dytor reached ₹650 crores with 25% YoY growth.
- Brand depth expanding: Four new brands crossed the ₹100 crore mark, taking the total to 33 such brands; Cipla now has 23 brands in the top 300.
- Differentiated launches driving momentum: New products included Foracort G Synchrobreathe, Ciphaler, Voltido Trio in respiratory; ZEMDRI and Cipenmet-Esblocip in antimicrobial resistance; XTIKTR in urology; Empagliflozin in diabetes; and Pirfesca in dermatology.
- Partnerships add heft: The Eli Lilly collaboration for Yurpeak (obesity), Mannkind Corporation for Afrezza (inhaled insulin), exclusive rights to Pfizer's key established brands, and the Inzpera Healthcare acquisition all contributed to the quarter. In-licensed Pfizer products specifically aided double-digit India growth in Q4.
- Trade generics and consumer health scaling: Trade generics continued double-digit YoY growth with 17 new launches planned this year. Consumer health brands Nicotex, Omnigel and Cipladine consolidated #1 positions, with operating profitability improving as the segment scales.
- Confidence in the trajectory: Management expressed confidence in sustaining strong double-digit, market-beating growth in both FY27 and FY28, with chronic diversification reducing dependence on acute seasonality that had muted Q1 branded Rx in the prior year.
U.S. Business: The Respiratory Catalyst
- The Ventolin unlock: Cipla received approval for the first AB-rated generic Ventolin with a CGT designation, the first commercial MDI product manufactured at its U.S. facility. Launch is expected in Q1, with a ramp-up in H2, and the 6-month CGT exclusivity provides an early window with limited competition.
- Three more respiratory assets in FY27: Advair (pre-approval inspection completed, approval expected during the year), Symbicort, and one additional asset are all slated for commercialization, split between H1 and H2. Four more respiratory assets are planned for filing over the next 24 months, including two with green propellant technology.
- The $1 billion run-rate target: Management clarified the goal is a run rate by end of FY27, not full-year revenue, because it is contingent on pipeline maturation. The math requires the Ventolin approval already in hand, three other respiratory approvals, one large peptide approval, and three smaller approved products. Lanreotide is explicitly excluded from this guidance and represents upside if resolved.
- Albuterol share stable: The 0.4% dip from 22% to 19.6% was described as not meaningful; management pencils in a 19%–20% range and noted share could increase if more supply were available.
- Regulatory momentum: U.S. FDA inspections at Bommasandra (Bangalore), Sitec (Mumbai), and Medispray (Goa) all resulted in VAI or NAI classifications. The Goa site, recently inspected with two observations, has a response submitted and is awaiting classification.
- Indore derisked: Following the regulatory issue, assets are now filed from U.S. and Goa sites; prospective filings are also focused on Goa and U.S. facilities. Indore will be accelerated once cleared, but management did not directly answer whether the classification itself is causing filing delays.
- Pipeline depth beyond respiratory: Nearly 40–50 products are to be filed over the next three years, including 12 first-to-files and 8 B2 opportunities. Peptides have 8 assets already filed with select launches projected in FY27–28, and 3 more filings planned in the next 12–24 months.
Achin Gupta: "We remain very confident in our U.S. business outlook, which is supported by a pipeline of nearly 40 to 50 products to be filed over the next 3 years."
Margins: Back-Half Weighted Recovery
- FY27 EBITDA guided to 18.5%–20%: The range implies sequential improvement quarter-on-quarter, with the key step-up concentrated in H2. The guidance does not include any contribution from Lanreotide.
- What drags H1: North America facilities carried costs in the last 1–2 quarters without commensurate revenue; economies of scale will improve as new respiratory launches ramp through the year. Some geopolitical and war-related sourcing disruption had a Q4 impact, with a small Q1 carryover and a possible H2 hit as inventories are consumed.
- What lifts H2: New product launches scaling up, facility utilization improving, and cost rationalization measures including technology transformation beginning to show results.
- Gross margin dynamics are mixed: Q4 gross margin improved sequentially because R&D material cost was lower. Lenalidomide carried high margins, but most respiratory assets are in-house and sit at the higher end of the margin range. Partnered peptides involve profit share or royalty that reduces gross margin but remains EBITDA-accretive. India's chronic portfolio delivers 5%–10% better gross margin than the acute mix.
- Longer-term margin ambition: Management stated that 20%+ EBITDA is "something that we should anyway sustain going forward," with a positive long-term bias on gross margins, though temporary blips from geopolitical risk are possible.
Ashish Adukia: "We expect the EBITDA margins to be in the range of 18.5% to 20% and this would be actually achieved with a sequential improvement quarter-on-quarter with the key improvement being in the second half of the year."
Biosimilars & Complex Generics: The Next Leg
- A declared strategic priority: Management framed biosimilars as a "very large and underpenetrated opportunity," citing roughly 100 biologics expected to lose exclusivity over the next decade, representing an almost $200 billion addressable market.
- In-house pipeline taking shape: Two global biosimilar assets are under development, one in a clinical study under a U.S. IND and one at an earlier stage. The plan is to add 1–2 assets each year, building to a pipeline of 6–8 in-house assets over the next 5–8 years.
- JV with Kemwell focused on execution: The joint venture carries an initial pipeline of respiratory and oncology assets, with plans to add 1–2 assets in-house through this vehicle.
- Near-term gap filled by in-licensing: Management is considering limited in-licensing for nearer-term opportunities while the internal pipeline matures.
- Peptides progressing: Eight assets filed, with select launches projected in FY27–28; three more filings planned over the next 12–24 months. Oligonucleotides are also in the works, though at an early stage.
- Lanreotide remediation underway: Partner remediation is in full swing, with closer visibility on timelines including FDA reinspection expected next quarter. An alternate U.S.-based manufacturing site has been identified, with a filing target of early next calendar year or Q4 of this financial year, implying a return to market from FY28.
Achin Gupta: "We see biosimilars as a very large and underpenetrated opportunity. And with the recent change in some of the guidelines... we believe this to be an upcoming almost $200 billion opportunity with around 100 such biologics expected to lose exclusivity over the next decade."
Capital Allocation & the M&A Option
- Cash position is deliberate: Net cash equivalents stood at ₹10,526 crores against debt (including lease liabilities) of ₹614 crores. Management is not worried about the cash level, viewing it as flexibility for 1–2 large, meaningful transactions.
- R&D investment accelerating: R&D spend was ₹509 crores (7.8% of revenue) in Q4 and ₹1,974 crores (7%) for FY26. Per-filing costs are rising because the pipeline is shifting toward complex products: respiratory, peptides, oligonucleotides including first-to-files, plus associated litigation, API, and CRO/CMO costs. Management declined to give a per-ANDA average, calling it too case-specific.
- Capex cycle nearing its peak: The current investment cycle has approximately one more year to run before tapering, which should ease the cash burden.
- Inorganic priorities: The bias is toward differentiated specialty products for the U.S. and Europe. A large India acquisition is difficult due to portfolio overlap. Emerging markets in Europe are seen as a good opportunity.
- Selectivity remains the watchword: Management emphasized remaining selective despite the cash balance, suggesting no urgency to deploy capital for its own sake.
Ashish Adukia: "If you were to chase 1 or 2 large transactions, meaningful transactions, this is not a very high amount of cash. So I don't think we are worried about the cash on our books." [16–17]
International Markets: Steady Contributors
- One Africa: Q4 grew 14% YoY in USD, with full-year growth of 7% YoY. Private market secondary growth outpaced the market at 6.6% versus 4.8%. South Africa's focus is on improving the private mix with a correction in tender contribution.
- EMEU: Breached the USD 400 million revenue mark despite geopolitical volatility and war. Growth was led by DTM and B2B categories, with consistent margin stability and internal pipeline assets. The strategy is to deepen penetration in core markets while maintaining the margin trajectory.
- No meaningful EU tariff impact: When asked whether Cipla benefits from sourcing basic devices from Europe for its respiratory portfolio, management said they are not expecting any meaningful impact and characterized it as business as usual, with no change in the duty structure.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| U.S. revenue run rate | Reach $1 billion run rate, contingent on pipeline maturing (excludes Lanreotide) | By end of FY27 |
| FY27 EBITDA margin | 18.5% to 20%, with sequential QoQ improvement and key step-up in H2 | FY27 full year |
| Generic Ventolin launch | First AB-rated generic with CGT, manufactured at U.S. facility | Q1 FY27 (ramp-up in H2) |
| Advair approval | Pre-approval inspection completed on U.S. facility | During FY27 |
| Respiratory filings | 4 additional assets for filing, including 2 with green propellant | Over next 24 months |
| Peptide launches | Select launches from 8 filed assets | FY27–28 |
| Biosimilar pipeline build | Add 1–2 assets each year toward 6–8 in-house assets | Over next 5–8 years |
| Lanreotide refiling | Alternate U.S. site identified; partner remediation in progress | Early next calendar year or Q4 FY27 |
| India growth | Strong double-digit, market-beating growth | FY27 and FY28 |
| U.S. pipeline filings | 40–50 products filed, including 12 first-to-files and 8 B2 opportunities | Over next 3 years |
| Trade generics launches | 17 new product launches | FY27 |
| EBITDA margin aspiration | Sustain 20%+ | Beyond FY27 |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue | ₹6,541 cr, FY26 revenue ₹28,163 cr |
| EBITDA margin | 15.2% (excl. other income), FY26 margin 21% |
| Gross margin | 65.6% (after material costs), FY26 margin 66% |
| PAT | ₹555 cr, 8.5% of sales, effective tax rate 22.2% |
| R&D spend | ₹509 cr, 7.8% of revenue; FY26 ₹1,974 cr at 7% of revenue |
| Total expenses | ₹3,296 cr, up ~10% YoY; FY26 ₹12,689 cr |
| Net cash | ₹10,526 cr, debt incl. lease liabilities ₹614 cr |
| ROIC | 22.9% for FY26 |
| One India revenue growth | 15% YoY, FY26 growth 9% YoY |
| North America revenue | $155 mn, FY26 revenue $780 mn |
| Albuterol market share | 19.6% as per IQVIA MAT March '26 |
| One Africa revenue growth | 14% YoY in USD terms, FY26 growth 7% YoY |
| EMEU revenue | breached $400 mn mark for FY26 |
| Chronic mix (India) | 60% as per IQVIA MAT March '26 |
| FY27 EBITDA margin guidance | 18.5% to 20%, sequential improvement QoQ, key improvement in H2, excludes Lanreotide contribution |
| U.S. revenue run-rate target | $1 bn exit run rate by end of FY27, not full-year revenue |